SCHEMBL29622845

SCHEMBL29622845

COc1ccc(F)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.53
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 3/20 0.53
HPGD P15428 2/20 0.53
HTT P42858 2/20 0.53
LMNA P02545 2/20 0.53
RAB9A P51151 2/20 0.53
MAPK1 P28482 1/20 0.53
LCK P06239 1/20 0.52
FYN P06241 1/20 0.52
HSD17B10 Q99714 1/20 0.51
PIN1 Q13526 4/20 0.49
MAPT P10636 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA4 P22748 1/20 0.48
CA6 P23280 1/20 0.48
CA7 P43166 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL113562 1.00 KEAP1 (0.53) KEAP1KDM4EALDH1A1HPGDHTT
SCHEMBL29881332 0.87 KEAP1 (0.49) KEAP1KDM4EALDH1A1HPGDHTT
SCHEMBL11692501 0.86 CFD (0.56) KDM4EALDH1A1HPGDHTTLMNA
SCHEMBL927338 0.85 ALDH1A1 (0.62) KEAP1KDM4EALDH1A1HPGDHTT
SCHEMBL30675620 0.85 ALDH1A1 (0.62) KEAP1KDM4EALDH1A1HPGDHTT
SCHEMBL43492 0.85 PIN1 (0.49) KDM4EALDH1A1HTTLMNARAB9A
SCHEMBL2328719 0.83 PIN1 (0.48) HTTLMNARAB9AMAPK1PIN1
SCHEMBL4300383 0.83 SMN1; SMN2 (0.52) KDM4EALDH1A1HPGDHTTLMNA
Hydrochloric Acid SCHEMBL10990786 0.83 ALDH1A1 (0.61) KEAP1KDM4EALDH1A1HPGDHTT
SCHEMBL29406733 0.83 PIN1 (0.50) ALDH1A1HPGDHTTLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634184-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY Crossfire Oncology Holding B.V. (NL) 2025-10-22 EP disclosed
EP-4583870-A2 MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER Mito Biopharma, LLC (US) 2025-07-16 EP disclosed
WO-2025083736-A1 NOVEL PROCESS FOR THE PREPARATION OF PIRTOBRUTINIB AND ITS INTERMEDIATES THEREOF MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2025-04-24 WO disclosed
CN-119735529-A Benzamide compound and application thereof in preparation of sensitizer of pseudomonas aeruginosa inhibitor 海南大学 2025-04-01 CN disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
EP-4448521-A1 REVERSIBLE MACROCYCLIC KINASE INHIBITORS Crossfire Oncology Holding B.V. (NL) 2024-10-23 EP disclosed
WO-2024126617-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2024-06-20 WO disclosed
EP-4337203-A1 INHIBITORS OF THE MENIN-MLL INTERACTION Syndax Pharmaceuticals, Inc. (US) 2024-03-20 EP disclosed
WO-2024054766-A2 MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER MITO BIOPHARMA, LLC (US) 2024-03-14 WO disclosed
WO-2023110936-A1 REVERSIBLE MACROCYCLIC KINASE INHIBITORS NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) 2023-06-22 WO disclosed
WO-2022241265-A1 INHIBITORS OF THE MENIN-MLL INTERACTION SYNDAX PHARMACEUTICALS, INC. (US) 2022-11-17 WO disclosed
EP-4013440-A1 THERAPEUTIC PEPTIDES Cohbar Inc. (US) 2022-06-22 EP disclosed